Q-omics provides the consensus-scored ZNF687 profile across patient tissues and cancer cell-line models. ZNF687 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNF687 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ZNF687 protein abundance shows 27,856 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where ZNF687 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF687 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF687 survival associations across molecular data types. ZNF687 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (12) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF687 RNA expression–survival associations across cancer types. High ZNF687 expression shows unfavorable associations in ACC and KICH, but favorable associations in KIRC, UVM, HNSC and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNF687 RNA expression.
This table summarizes ZNF687 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF687. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF687 shows higher tumor expression in HNSC, LIHC, BLCA, LUAD, COAD and BRCA. The HNSC box plot shows higher ZNF687 RNA expression in tumor versus normal tissue (log2 FC = +0.841, t-test p < 0.001).
This table shows molecular features associated with ZNF687 in patient tissues and cancer cell lines. In patient samples, ZNF687 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF687 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
